pubmed.ncbi.nlm.nih.gov

Thrombocytosis as a Biomarker in Type II, Non-Endometrioid Endometrial Cancer - PubMed

  • ️Wed Jan 01 2020

Thrombocytosis as a Biomarker in Type II, Non-Endometrioid Endometrial Cancer

Parker Bussies et al. Cancers (Basel). 2020.

Abstract

Thrombocytosis (platelets ≥ 400K) is a common hematologic finding in gynecologic malignancies and associated with worse outcomes. Limited data exist on the prognostic capability of thrombocytosis in women with high-grade endometrial cancer (EC). Our objective was to describe the associations between elevated platelets at diagnosis, clinicopathologic features, and survival outcomes among women with high-grade, non-endometrioid EC. A review of the institutional cancer registry was performed to identify these women treated between 2005 and 2017. Sociodemographic, clinical, and outcomes data were collected. Analyses were performed using chi-square tests, Cox proportional hazards models, and the Kaplan-Meier method. A total of 271 women were included in the analysis. A total of 19.3% of women had thrombocytosis at diagnosis. Thrombocytosis was associated with reduced median overall survival (OS) compared with those not displaying thrombocytosis (29.4 months vs. 60 months, p < 0.01). This finding was most pronounced in uterine serous carcinoma (16.4 months with thrombocytosis vs. 34.4 months without, p < 0.01). While non-White women had shorter median OS for the whole cohort in the setting of thrombocytosis (29.4 months vs. 39.6 months, p < 0.01), among those with uterine serous carcinoma (USC), this finding was reversed, with decreased median OS in White women (22.1 vs. 16.4 months, p = 0.01). Thrombocytosis is concluded to have negative associations with OS and patient race.

Keywords: endometrial cancer; platelets; race; serous; survival; thrombocytosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1

Unadjusted overall survival by thrombocytosis. Median overall survival (OS) was significantly affected by presence of thrombocytosis. Median OS of those with thrombocytosis was 29.4 months compared to 60 months in those without thrombocytosis (log-rank p = 0.007).

Figure 2
Figure 2

Unadjusted overall survival by thrombocytosis and histology. Median overall survival (OS) of all patients stratified by the thrombocytosis and serous histology. Median OS of non-serous tumors with thrombocytosis was 50 months and was 95.9 months for non-serous tumors without thrombocytosis. In contrast, serous tumors with thrombocytosis had a median OS of 16.4 months, and serous tumors without thrombocytosis had a median OS of 34.4 months (p < 0.001).

Figure 3
Figure 3

Overall survival by thrombocytosis and race in (a) the entire high-grade endometrial cohort (log-rank p = 0.008) and (b) serous carcinomas only (p = 0.01).

Similar articles

Cited by

References

    1. Siegel R., Miller K., Jemal A. Cancer Statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Bokhman J. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983;15:10–17. doi: 10.1016/0090-8258(83)90111-7. - DOI - PubMed
    1. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I. Endometrial cancer. Lancet. 2005;366:491–505. doi: 10.1016/S0140-6736(05)67063-8. - DOI - PubMed
    1. Felix A., Weissfeld J., Stone R., Bowser R., Chivukula M., Edwards R., Linkov F. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010;21:1851–1856. doi: 10.1007/s10552-010-9612-8. - DOI - PMC - PubMed
    1. Amant F., Mirza M., Koskas M., Creutzberg C. Cancer of the corpus uteri. Int. J. Gynaecol. Obstet. 2018;143:37–50. doi: 10.1002/ijgo.12612. - DOI - PubMed

LinkOut - more resources